eGFR降低的老年患者接受直接口服抗凝药的心血管事件与死亡风险
该回顾性队列研究纳入2009至2016年加拿大安大略省66岁以上首次口服抗凝药者,将27552例DOAC使用者与27552例VKA使用者倾向评分匹配。DOAC组主要复合终点(心血管事件或死亡)及出血住院风险均低于VKA组,且eGFR与主要终点存在交互作用,eGFR 30-59组中DOAC获益更明显。
要点
- 老年口服抗凝患者中,DOAC较VKA降低心血管事件或死亡复合风险(HR 0.82)。
- DOAC较VKA降低出血住院风险(HR 0.73)。
- eGFR与主要终点存在交互作用,eGFR 30-59组DOAC获益更明显。
核心结论
- 与VKA相比,DOAC与较低的心血管事件或死亡复合风险相关,且在eGFR降低者中关联强度更明显。
研究设计与样本
- 基于人群的回顾性队列研究,纳入2009至2016年加拿大安大略省66岁及以上首次口服抗凝药者。
- 27552例DOAC新使用者与27552例VKA新使用者经高维倾向评分匹配,中位年龄78岁,女性49%。
- 按eGFR分组(≥60、30-59、<30 mL/min/1.73m2)比较DOAC与VKA,采用Cox比例风险回归。
主要发现
- DOAC组与VKA组主要复合终点事件率分别为79.78 vs 99.77/1000人年,HR 0.82(95%CI 0.75-0.90)。
- DOAC组与VKA组出血住院事件率分别为10.35 vs 16.77/1000人年,HR 0.73(95%CI 0.58-0.91)。
- eGFR与主要复合终点存在交互作用(P<0.02),eGFR≥60、30-59、<30 mL/min/1.73m2的HR分别为1.01(95%CI 0.92-1.12)、0.83(95%CI 0.75-0.93)、0.75(95%CI 0.51-1.10)。
- 出血结局未检测到交互作用。
临床怎么用
- 老年口服抗凝患者选择DOAC而非VKA可能降低心血管事件或死亡及出血住院风险,尤其eGFR 30-59者。
局限性
- 回顾性观察设计限制因果推断。
- 缺乏DOAC剂量及国际标准化比值数据。
- 部分亚组事件率低限制统计效能。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
RATIONALE & OBJECTIVE: Evidence for the efficacy of direct oral anticoagulants (DOACs) to prevent cardiovascular (CV) events and mortality in older individuals with a low estimated glomerular filtration rate (eGFR) is lacking. We sought to characterize the association of oral anticoagulant use with CV morbidity in elderly patients with or without reductions in eGFRs, comparing DOACs with vitamin K antagonists (VKAs). STUDY DESIGN: Population-based retrospective cohort study. SETTINGS & PARTICIPANTS: All individuals 66 years or older with an initial prescription for oral anticoagulants dispensed in Ontario, Canada, from 2009 to 2016. EXPOSURE: DOACs (apixaban, dabigatran, and rivaroxaban) compared with VKAs by eGFR group (≥60, 30-59, and<30mL/min/1.73m2). OUTCOMES: The primary outcome was a composite of a CV event (myocardial infarction, revascularization, or ischemic stroke) or mortality. Secondary outcomes were CV events alone, mortality, and hemorrhage requiring hospitalization. ANALYTICAL APPROACH: High-dimensional propensity score matching of DOAC to VKA users and Cox proportional hazards regression. RESULTS: 27,552 new DOAC users were matched to 27,552 new VKA users (median age, 78 years; 49% women). There was significantly lower risk for CV events or mortality among DOAC users compared with VKA users (event rates of 79.78 vs 99.77 per 1,000 person-years, respectively; HR, 0.82 [95% CI, 0.75-0.90]) and lower risk for hemorrhage (event rates of 10.35 vs 16.77 per 1,000 person-years, respectively; HR, 0.73 [95% CI, 0.58-0.91]). There was an interaction between eGFR and the association of anticoagulant class with the primary composite outcome (P<0.02): HRs of 1.01 [95% CI, 0.92-1.12], 0.83 [95% CI, 0.75-0.93], and 0.75 [95% CI, 0.51-1.10] for eGFRs of≥60, 30 to 59, and<30mL/min/1.73m2. No interaction was detected for the outcome of hemorrhage. LIMITATIONS: Retrospective observational study design limits causal inference; dosages of DOACs and international normalized ratio values were not available; low event rates in some subgroups limited statistical power. CONCLUSIONS: DOACs compared with VKAs were associated with lower risk for the composite of CV events or mortality, an association for which the strength was most apparent among those with reduced eGFRs. The therapeutic implications of these findings await further study.
引用
- Ashley J, McArthur E, Bota S, et al. Risk of Cardiovascular Events and Mortality Among Elderly Patients With Reduced GFR Receiving Direct Oral Anticoagulants. Am J Kidney Dis. 2020. PMID: 32333946. doi:10.1053/j.ajkd.2020.02.446
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。